HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.

You may also be interested in...

Matrixx Appoints Scerene Healthcare Executive To Lead Turnaround

M’lou Arnett talks about how her experience, including designing the “Mr. Mucus” advertising icon for the Mucinex cough treatment line, has prepared her for the challenge of growing Matrixx’s revenues in the wake of removing the Zicam gel and swab products from the market.

Zicam Maker Matrixx Settles With Shareholders Over H.I.G. Buyout

Matrixx Initiatives remains mired in multiple lawsuits despite settling litigation with shareholders over the firm’s handling of its 2010 buyout.

Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden

The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts